Ju-Hwa Kim

535 total citations
14 papers, 448 citations indexed

About

Ju-Hwa Kim is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Ju-Hwa Kim has authored 14 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Ju-Hwa Kim's work include Drug Transport and Resistance Mechanisms (5 papers), Cancer therapeutics and mechanisms (4 papers) and Cancer Cells and Metastasis (3 papers). Ju-Hwa Kim is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Cancer therapeutics and mechanisms (4 papers) and Cancer Cells and Metastasis (3 papers). Ju-Hwa Kim collaborates with scholars based in South Korea. Ju-Hwa Kim's co-authors include Sungpil Yoon, Ae‐Ran Choi, Han Sung Kang, Jungsil Ro, Hyung Sik Kim, Kyungsil Yoon, Sunshin Kim, Yong Kee Kim, Tae Hyung Kim and Young‐Su Yi and has published in prestigious journals such as Biochemical and Biophysical Research Communications, International Journal of Molecular Sciences and Biochemical Pharmacology.

In The Last Decade

Ju-Hwa Kim

14 papers receiving 446 citations

Peers

Ju-Hwa Kim

ONCOL

PFM

EPIDE

Sumaiya Sharmeen Canada

Junmei Hou China

Estelle G. McLean United Kingdom

Yongping Cui China

Glenn S. Van Aller United States

Eloisi Caldas Lopes United States

Satadal Chatterjee United States

R Zhang United States

Mingmei Liao China

Chunwan Lu United States

Sumaiya Sharmeen Canada

Ju-Hwa Kim

204 ×0.7

218 ×0.9

ONCOL

83 ×1.1

PFM

40 ×0.8

20 ×0.6

EPIDE

Citations per year, relative to Ju-Hwa Kim Ju-Hwa Kim (= 1×) peers Sumaiya Sharmeen

Countries citing papers authored by Ju-Hwa Kim

Since Specialization

Citations

This map shows the geographic impact of Ju-Hwa Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ju-Hwa Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ju-Hwa Kim more than expected).

Fields of papers citing papers by Ju-Hwa Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ju-Hwa Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ju-Hwa Kim. The network helps show where Ju-Hwa Kim may publish in the future.

Co-authorship network of co-authors of Ju-Hwa Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Ju-Hwa Kim. A scholar is included among the top collaborators of Ju-Hwa Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ju-Hwa Kim. Ju-Hwa Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Choi, Ae‐Ran, et al.. (2016). Attenuation of Colchicine Toxicity in Drug-resistant Cancer Cells by Co-treatment with Anti-malarial Drugs. Anticancer Research. 36(11). 5859–5866. 35 indexed citations

Choi, Ae‐Ran, et al.. (2016). Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT. Anticancer Research. 36(11). 5849–5858. 24 indexed citations

Choi, Ae‐Ran, et al.. (2016). Anti-malarial Drugs Primaquine and Chloroquine Have Different Sensitization Effects with Anti-mitotic Drugs in Resistant Cancer Cells.. PubMed. 36(4). 1641–8. 33 indexed citations

Choi, Ae‐Ran, et al.. (2015). Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis.. PubMed. 35(9). 4741–7. 10 indexed citations

Choi, Ae‐Ran, Ju-Hwa Kim, & Sungpil Yoon. (2014). Thioridazine specifically sensitizes drug-resistant cancer cells through highly increase in apoptosis and P-gp inhibition. Tumor Biology. 35(10). 9831–9838. 19 indexed citations

Choi, Ae‐Ran, Ju-Hwa Kim, & Sungpil Yoon. (2014). Sensitization of Cancer Cells through Reduction of Total Akt and Downregulation of Salinomycin-Induced pAkt, pGSk3β, pTSC2, and p4EBP1 by Cotreatment with MK-2206. BioMed Research International. 2014. 1–8. 16 indexed citations

Kim, Ju-Hwa, et al.. (2013). SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition. European Journal of Pharmacology. 723. 141–147. 20 indexed citations

Kim, Ju-Hwa, Ae‐Ran Choi, Yong Kee Kim, & Sungpil Yoon. (2013). Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition. Biochemical and Biophysical Research Communications. 441(3). 655–660. 32 indexed citations

Kim, Ju-Hwa, et al.. (2012). Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochemical and Biophysical Research Communications. 418(1). 98–103. 68 indexed citations

10.

Kim, Ju-Hwa, Tae Il Kim, Hyung Joon Kim, Suntaek Hong, & Sungpil Yoon. (2012). Lower Salinomycin Concentration Increases Apoptotic Detachment in High-Density Cancer Cells. International Journal of Molecular Sciences. 13(10). 13169–13182. 14 indexed citations

11.

Kim, Ju-Hwa, Kyungsil Yoon, Sunshin Kim, et al.. (2011). Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Investigational New Drugs. 30(4). 1311–1318. 63 indexed citations

12.

Yoon, Sungpil, Young‐Su Yi, Sang Soo Kim, et al.. (2011). SOCS5 and SOCS6 have similar expression patterns in normal and cancer tissues. Tumor Biology. 33(1). 215–221. 26 indexed citations

13.

Kim, Ju-Hwa, Tae Hyung Kim, Han Sung Kang, et al.. (2009). SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin. Biochemical and Biophysical Research Communications. 387(3). 450–455. 27 indexed citations

14.

Kim, Ju-Hwa, et al.. (2009). Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines. Biochemical Pharmacology. 79(3). 373–380. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact